Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain
Sign Up to like & getrecommendations! Published in 2022 at "PharmacoEconomics - Open"
DOI: 10.1007/s41669-022-00322-w
Abstract: This study aimed to assess the potential epidemiological and economic impact of rapid initiation of human immunodeficiency virus (HIV) treatment with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) on HIV transmission compared with the current initiation observed in clinical… read more here.
Keywords: analysis; art initiation; art; hiv ... See more keywords
Impact of Pre-Existing Nrti Resistance on the Effectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experience Patients: Real-World Data.
Sign Up to like & getrecommendations! Published in 2022 at "AIDS"
DOI: 10.1097/qad.0000000000003311
Abstract: INTRODUCTION Few clinical trials and cohort studies have evaluated the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) with preexisting M184V/I or other nucleos(t)ide reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs). Real-world data… read more here.
Keywords: analysis; resistance; tenofovir; real world ... See more keywords
Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance
Sign Up to like & getrecommendations! Published in 2022 at "HIV Medicine"
DOI: 10.1111/hiv.13376
Abstract: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is approved for treatment of HIV without known resistance to its components. Several studies have demonstrated efficacy of B/F/TAF in patients with nucleoside reverse transcriptase inhibitor (NRTI) resistance‐associated mutations (RAMs), mainly identified… read more here.
Keywords: emtricitabine tenofovir; nrti resistance; bictegravir emtricitabine; resistance ... See more keywords
Intermittent Bictegravir/Emtricitabine/Tenofovir Alafenamide Treatment Maintains High Level of Viral Suppression in Virally Suppressed People Living with HIV
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Personalized Medicine"
DOI: 10.3390/jpm13040583
Abstract: In this observational study, we aimed to evaluate whether bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered 5 or 4 days a week is able to maintain viral suppression in people living with HIV (PLHIV). We enrolled 85 patients… read more here.
Keywords: emtricitabine tenofovir; people living; bictegravir emtricitabine; viral suppression ... See more keywords
Immune Reconstitution and Safe Metabolic Profile after the Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide Fumarate among Virologically Controlled PLWH: A 96 Week Update from the BICTEL Cohort
Sign Up to like & getrecommendations! Published in 2023 at "Viruses"
DOI: 10.3390/v15061222
Abstract: Background: Bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) is a recommended once-daily single-tablet regimen for the treatment of people living with HIV (PLWH). We aimed to assess efficacy, safety, and tolerability of BIC/FTC/TAF among PLWH, with a specific… read more here.
Keywords: plwh; switch; emtricitabine tenofovir; bictegravir emtricitabine ... See more keywords